

United States Patent and Trademark Office

cl

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/660,607	09/12/2003	David H. Mack	003848.00131	7415	
28315	7590 11/03/2005		EXAMINER		
BANNER & WITCOFF LTD., COUNSEL FOR AFFYMETRIX 1001 G STREET , N.W. ELEVENTH FLOOR			GOLDBERG, JEANINE ANNE		
			ART UNIT	PAPER NUMBER	
			1634		
WASHINGTO	ON, DC 20001-4597		DATE MAILED: 11/03/2005	5	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	on No.	Applicant(s)				
Office Action Summary		10/660,60)7	MACK, DAVID H.				
		Examiner		Art Unit				
		Jeanine A	. Goldberg	1634				
 Period for	The MAILING DATE of this communication a Reply	appears on the	cover sheet with the c	correspondence ac	ddress			
WHICH - Extension after SD - If NO pe - Failure to Any rep	RTENED STATUTORY PERIOD FOR REF EVER IS LONGER, FROM THE MAILING ons of time may be available under the provisions of 37 CFR (6) MONTHS from the mailing date of this communication. eriod for reply is specified above, the maximum statutory peri- to reply within the set or extended period for reply will, by stat by received by the Office later than three months after the ma- patent term adjustment. See 37 CFR 1.704(b).	DATE OF TH 1.136(a). In no eve od will apply and wi tute, cause the appl	IIS COMMUNICATION ont, however, may a reply be tin II expire SIX (6) MONTHS from ication to become ABANDONE	N. nely filed the mailing date of this c D (35 U.S.C. § 133).				
Status								
1)⊠ R	espansive to communication(s) filed on 12	Sentember 2	ยกกร					
<i>'</i> =	Responsive to communication(s) filed on <u>12 September 2003</u> . This action is FINAL . 2b) This action is non-final.							
,—								
-	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
	n of Claims	panto qu						
		oloro nondina	in the application					
•	Claim(s) <u>18-28,39,40,44-106 and 109-129</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
·								
<u> </u>	· · · · · · · · · · · · · · · · · · ·							
·	(')☐ Claim(s) is/are objected to. (S)☑ Claim(s) <u>18-28,39,40,44-106 and 109-129</u> are subject to restriction and/or election requirement.							
8)[2] C	iaim(s) <u>18-28,39,40,44-106 and 109-129</u> a ·	ire subject to	estriction and/or elect	don requirement.				
Application	n Papers				•			
9)□ Th	ne specification is objected to by the Exam	iner.			•			
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority un	der 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
- a)□	a) ☐ All b) ☐ Some * c) ☐ None of:							
1	1. Certified copies of the priority documents have been received.							
2	2. Certified copies of the priority documents have been received in Application No							
3	3. Copies of the certified copies of the priority documents have been received in this National Stage							
	application from the International Bur	eau (PCT Rul	e 17.2(a)).					
* Se	e the attached detailed Office action for a l	ist of the certi	fied copies not receive	ed.				
Attachment(s)	•						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)								
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)			Paper No(s)/Mail D	ate	O 453)			
, —	tion Disclosure Statement(s) (PTO-1449 or PTO/SB/l lo(s)/Mail Date	08)	5) Notice of Informal Patent Application (PTO-152) 6) Other:					

DETAILED ACTION

Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 18-28, drawn to method for determining gene function, classified in class 435, subclass 6.
 - II. Claims 39-40 & 99-106, drawn to an array of nucleic acid probes, classified in class 536, subclass 24.3.
 - III. Claims 44 & 45, drawn to a method for analyzing gene expression using a computer, classified in class 364, subclass 920.
 - IV. Claims 46-94, drawn to a method of diagnosis using hybridization, classified in class 435, subclass 6.
 - V. Claims 95-98, drawn to a method of identifying drugs, classified in class 435, subclass 70.1.
 - VI. Claims 109-115, drawn to a method of identifying drugs, classified in class 435, subclass 70.1.
 - VII. Claims 116-129, drawn to method of determining cell state, classified in class 435, subclass 6.
- 2. Inventions II and I & III-VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used

in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process such as a template for amplifying nucleic acids or for making labeled probes.

- 3. Inventions I, III-VII are independent and distinct inventions. Inventions are independent and distinct if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation because they are methods having different method steps, different functions, different effects, and because they have different results such as mapping a gene network (invention I), detecting and comparing gene expression (invention II), determining gene function (invention III), analyzing gene expression (invention IV), diagnosing gene expression pattern (invention VI), identifying a compound as an anti-cancer drug (invention VIII), analyzing gene expression under drug pressure (invention VIII), determining the state or stage of cells or tissue (invention IX), and using an in-cell assay to analyze specific gene function (invention X).
- 4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CAR 1.143).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jeanine Goldberg whose telephone number is (571) 272-0743. The examiner can normally be reached Monday-Friday from 7:00 a.m. to 4:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (571) 272- 0745.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

The Central Fax Number for official correspondence is (571) 273-8300.

Jeanine Goldberg

Primary Examiner October 31, 2005